Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ecopipam for self-injurious behavior in Lesch-Nyhan disease
NL-OMON37257Phase 3Withdrawn
- Sponsor
- Emalex Biosciences
- Start
- Nov 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ecopipam in Lesch-Nyhan syndrome (LNS), sponsored by Emalex Biosciences. Planned start Nov 2012; status: withdrawn.
02
Drugs
ecopipam
03
Conditions
Lesch-Nyhan syndrome (LNS)
Beyond the preview
Go deeper on NL-OMON37257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37257.